New to HBW Insight?
Start a free trial today!
Register for our free email digests:
Register for our free email digests:
Tom Gallen
Managing Editor – Europe
Having joined OTC bulletin as a business reporter in 2013, Tom is currently the managing editor and has an intimate knowledge of the global consumer healthcare market, particularly commercial and regulatory issues. He specializes in analyzing the strategies of the world's leading consumer healthcare companies, their business performance, plans and product portfolios.
Remove Alert
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Tom Gallen
Germany's Neuraxpharm Underlines OTC Ambitions With Easypharm Acquisition
Austria's Easypharm has been snapped up by Neuraxpharm, which is looking to take a larger slice of Europe's consumer healthcare market.
Dermocosmetics Push Yields Results For Switzerland's Galenica
Launching skin-care products that blend "natural medicinal plants from the Swiss pharmacopoeia with the best Swiss skin science" helped to drive up Galenica's OTC sales in 2019 at a double-digit rate.
Polish Industry Fighting Against Advertising Tax On Supplements
Advertising dietary supplements in Poland will incur a new tax under proposals from the country's Ministry of Health. While the government claims the motivation is to promote healthy eating choices, industry says supplements have been unfairly linked to poor dietary choices without evidence.
French OTC Industry Frustrated By Regulatory Clampdown in 2019
Speaking exclusively to HBW Insight, French OTC association Afipa reflects on a difficult 2019 which saw tighter restrictions introduced on the sale of popular consumer health products. The trade group believes the industry's best prospects for a brighter future are rebuilding relations with national drug regulator ANSM and to getting self-care higher up the agenda of the French government.
No More ‘Major’ Deals For GSK Consumer Before IPO – CEO Walmsley
GSK's CEO Emma Walmsley has effectively ruled out further big deals at its Consumer Healthcare unit before the business is separated from its parent through an IPO.
HRA Pharma Taking On China With JV Partner
HRA is putting feet on the ground in China as it looks to establish itself in the world second-largest consumer health market.